Skip to main content

Immunome to Present at the Cantor Global Healthcare Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D., Immunome’s President and CEO, will present at the Cantor Global Healthcare Conference on Wednesday, September 29, 2021, at 8:40 a.m. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Immunome

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.70
+0.00 (0.00%)
AAPL  270.71
+0.00 (0.00%)
AMD  323.21
+0.00 (0.00%)
BAC  52.66
+0.00 (0.00%)
GOOG  347.50
+0.00 (0.00%)
META  671.34
+0.00 (0.00%)
MSFT  429.25
+0.00 (0.00%)
NVDA  213.17
+0.00 (0.00%)
ORCL  165.96
+0.00 (0.00%)
TSLA  376.02
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.